BCI Leader Science Corp. Appoints Darius Shahida as Chief Strategy Officer to Accelerate Strategic Growth and Commercialization of Prima BCI Retinal Implant
Butterfly Network
Developer of Artificial Intelligence Medical Imaging Equipment
Pixium Vision
Bionic Vision System and Device Developer
Neuralink
Brain-Computer Interface System Developer
Brain-Computer Interface (Science Corp., a leading enterprise in the brain-computer interface (BCI) sector, announced today the appointment of Darius Shahida as its new Chief Strategy Officer (CSO), effective January 5, 2026.
Shahida will report directly to the companyMax Hodak, CEO and Founder, reports directly to the board and holds full responsibility for capital fundraising, corporate and business development, and partnership expansion. Notably, Hodak is also a co-founder of Neuralink, another prominent brain-computer interface (BCI) company; his industry influence provides significant endorsement for Science Corp.’s growth.
NewCSO with an Impressive Track Record: A Strategic Growth Expert in the MedTech Sector
Before joining this Alameda, California-based company,Shahida previously served asChief Strategy Officer and Chief Business Development Officer of Butterfly NetworkDuring this period, he spearheaded the initial public offering (IPO) process for this handheld ultrasound technology developer, overseeing mergers and acquisitions, financing, business expansion, and corporate strategy formulation. He also managed the AI and global health businesses and led the establishment of Octiv, the company’s advanced semiconductor business unit.
“Darius has deep experience in strategic growth, capital markets, and helping to build and develop industry-defining medical technology companies,” commented Hodac. “As our company accelerates its growth, having leadership of this caliber focused on our critical funding needs and strategic growth is essential.”
Focus on Core Products:
The Commercialization Path of the Prima BCI Retinal Implant
Shahida's joining, coinciding withScience Corp. Advances Its First Product ——Prima BCI Retinal Implantkey stage. Acquired from Pixium Vision last year, this technology is a photovoltaic substitute for photoreceptors that has received the U.S. FDA Breakthrough Device designation. Its core advantage lies in enabling the simultaneous use of central artificial vision and peripheral natural vision.
Its working principle is as follows: when the patient’s rod and cone cells (retinal photoreceptor cells) are damaged,The Prima system helps patients restore vision by directly activating the retina. It achieves this by transmitting light signals to a small, light-driven implant placed beneath the retina, using specialized glasses equipped with a built-in camera and an infrared projector.
Currently, the commercialization of this product is progressing steadily: the company has alreadyIn June, commercial marketing applications were submitted to the United States and Europe; the patient registry program was launched in September, and positive clinical data were announced in October.
“Science has created a completely new type of company—one unlike anything I’ve seen before,” said Shahida. “From restoring vision to pushing the boundaries of neuroscience and biology to enhance human performance and extend longevity, Max and his team have demonstrated what the future of medicine looks like. After a fulfilling journey at Butterfly Network, I am thrilled to join Science at this pivotal juncture.”
Previous Recommendations
Financial Fraud: Countdown to Delisting for Leading Medical Device Company
Suzhou Medical Device Company Secures Nearly 100 Million Yuan in Financing!
